Liver Transplantation in the Obese Cirrhotic Patient

Erin K Spengler1, Jacqueline G O'Leary, Helen S Te

  • 11 Division of Gastroenterology and Hepatology, University of Wisconsin, Madison, WI.2 Division of Hepatology, Baylor University Medical Center, Dallas, TX.3 Center for Liver Diseases, University of Chicago Medicine, Chicago, IL.4 VA Pittsburgh Healthcare System, Department of Surgery, University of Pittsburgh, PA.5 Division of Digestive Diseases and The Emory Transplant Center, Emory University Hospital, Atlanta, GA.6 Division of Hepatology, Temple University Health System, Philadelphia, PA.7 Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona, Tucson, AZ.8 Department of Pharmacy, Medical University of South Carolina, Charleston, SC.9 Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL.10 Transplant Institute, Banner University of Arizona College of Medicine-Phoenix, Tucson, AZ.11 Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.12 Division of Transplantation, Department of Surgery. University of Washington. Seattle, WA.13 Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA.

Transplantation
|September 21, 2017
PubMed

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
226
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
312
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
552
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
512